Flu activity is rising sharply... these “on sale” names are worth
a look. ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏



 

[Morning Watchlist]

_You are receiving this email because you are subscribed to BEHIND THE
MARKETS. If you no longer wish to receive these emails,
please unsubscribe
[[link removed]] here._

_Prefer to view this content on our website? Click here.
[[link removed]]
_

-------------------------

THESE FLU SEASON STOCKS ARE ON SALE

Flu season is one of those unavoidable annual realities: it shows up,
it spreads fast, and it sends a meaningful portion of the country
looking for prevention, relief, and treatment, often all at once.

For consumers, that means flu shots, sanitizer, disinfecting wipes,
cough-and-cold aisles, and pharmacy runs. For investors, it often
means something else: a RECURRING SEASONAL TAILWIND for a handful of
well-positioned, high-visibility names.

And this year, the public-health backdrop is already getting intense.

The CDC’s most recent surveillance update (Week 51, reflecting data
through the week ending DECEMBER 20, 2025) estimates AT LEAST 7.5
MILLION FLU ILLNESSES, 81,000 HOSPITALIZATIONS, AND 3,100 DEATHS SO
FAR THIS SEASON, with EIGHT PEDIATRIC DEATHS reported to date.

That’s not just noise. It’s a real-time reminder that the “flu
season trade” is not theoretical in 2026, it’s happening.

-------------------------

THE SEASONAL REALITY: FLU IS A RECURRING MARKET CATALYST

Flu season isn’t pleasant, but it is predictable. And from a market
standpoint, predictable catalysts can create repeatable opportunities,
especially when investor attention rotates toward safety, consumer
staples, and healthcare access.

Context matters here:

*
For the 2023–2024 season, the CDC estimated 40 MILLION ILLNESSES,
470,000 HOSPITALIZATIONS, AND 28,000 DEATHS.

*
For 2024–2025, CDC summarized it as HIGH SEVERITY, with preliminary
estimates ranging as high as 43–73 MILLION SYMPTOMATIC ILLNESSES and
38,000–99,000 DEATHS, depending on the final modeling range.

And now, for 2026, early-season numbers are already elevated, with the
CDC recommending that everyone 6 MONTHS AND OLDER who hasn’t yet
been vaccinated get an annual flu shot.

When the data turns ugly, consumer behavior changes quickly:

*
More trips to pharmacies for vaccinations and OTC products

*
More spending on disinfecting and household cleaning

*
More attention to basic preventative measures and “sick day”
essentials

That’s why flu season often becomes a quietly powerful catalyst for
select stocks, particularly those that sit at the intersection of
HOUSEHOLD STAPLES + HEALTHCARE ACCESS.

Two names stand out right now because they combine that seasonal
tailwind with something investors love in uncertain tape: INCOME.

-------------------------

REVEALED: AMERICA JUST UNLOCKED A $500 TRILLION ASSET
[[link removed]]

Everyone's talking about AI stocks but almost no one is talking about
what AI actually runs on.

Nickel. Copper. Cobalt. Manganese.

America just secured exclusive rights to the largest untapped supply
on Earth.

One company is already in position and this could be one of the most
important AI infrastructure plays heading into 2026.

THE NAME AND TICKER ARE AVAILABLE HERE NOW >>>
[[link removed]]

-------------------------

Company: CLOROX (SYM: CLX)
YIELD, DEFENSIVENESS, AND A TIMELY SEASONAL SETUP

One of the simplest flu-season beneficiaries is also one of the most
straightforward to own: CLOROX.

When illness is spreading, demand tends to rise for cleaning and
disinfecting staples, exactly where Clorox has brand equity and shelf
presence. This isn’t a “get rich quick” story. It’s a
DEFENSIVE POSITIONING story with an embedded seasonal boost.

Right now, the setup is especially notable for income-focused
investors:

*
CLX is trading around $101 (roughly where it’s been highlighted as
oversold).

*
Dividend yield is approximately 4.9%, driven by an annualized dividend
around $4.96.

*
The company most recently declared a $1.24 QUARTERLY DIVIDEND, payable
FEBRUARY 13, 2026, to shareholders of record JANUARY 28, 2026.

That yield matters. In a market where investors often “rent”
momentum, a near-5% yield lets you get paid while you wait, especially
if the stock is already washed out and the seasonal narrative is
strengthening.

THE SEASONAL ANGLE

Historically, CLX has often shown strength as flu season approaches
and activity rises (frequently clustering around the fall-to-winter
window). There have been multiple years where CLX moved higher during
the flu-season build.

This year, the additional ingredient is POSITIONING: if shares are
already depressed, it can take less incremental buying to move the
stock. That’s exactly how “on sale” seasonal trades tend to
work. Bad sentiment sets the table, and a recurring catalyst supplies
the spark.

WHAT TO WATCH

CLX isn’t risk-free. If costs rise, volumes soften, or the market
rotates aggressively out of staples, you can still see downside. But
if you’re evaluating a flu-season basket, CLX offers a clear
combination of:

*
Defensive demand characteristics

*
Brand-driven pricing power (over time)

*
Income support via dividend

-------------------------

_Vantagepoint_

LEARN THE A.I. THAT PINPOINTS STOCKS SET TO SURGE
[[link removed]]

[vantage point]
[[link removed]]

President Trump's tariff negotiations and the Fed's hawkish pivot can
be summed up as "The Policy Collision."

Tesla, Google, Apple, and Nvidia dominate headlines, but their size
may limit explosive upside. Survival isn't surge.

VantagePoint's A.I. identifies the hidden opportunity: mid-cap
industrials and regional financials positioned for reshoring and
lending demand. The same up to 87.4% proven accurate forecasting that
called massive similar setups.

The next wave could hit within weeks. As tariffs and Fed policy
settle, capital is flowing fast.
[SEE THE TOP 3 VANTAGEPOINT A.I. FORECASTS FOR Q1 2026 →]
[[link removed]]
_(By clicking the links and image above, you will automatically
register and opt-in to receive emails from Vantagepoint A.I.)_

-------------------------

Company: CVS HEALTH (SYM: CVS)
FLU SHOTS, PHARMACY TRAFFIC, AND RECURRING SEASONAL DEMAND 

If Clorox captures the “home hygiene” spend, CVS captures the
“health access” spend.

Flu season creates more than just demand for OTC remedies, it drives
VACCINATIONS, PRESCRIPTIONS, RAPID TESTS, AND STORE TRAFFIC. CVS is
one of the most direct public-market ways to get that exposure at
scale.

As of JANUARY 2, 2026, CVS is trading around $80.

And CVS brings a meaningful income component as well:

*
Annual dividend is about $2.66 PER SHARE, implying a yield around 3.3%
at current levels.

*
The most recent quarterly dividend was $0.665 PER SHARE, paid on
NOVEMBER 3, 2025, to shareholders of record on OCTOBER 23, 2025.

WHY CVS FITS FLU SEASON

Even without “perfect” seasonality, the business model lines up
with how consumers behave when respiratory illness spikes:

*
Vaccination appointments and walk-ins

*
Rx fulfillment and refills

*
OTC basket-building (fever reducers, cough/cold, electrolytes, masks,
sanitizers)

And notably, the CDC’s surveillance update highlighted widespread
activity and a sharp rise in illness counts as of late December 2025.
That kind of surge tends to keep pharmacy traffic elevated into
January and beyond.

THE TACTICAL VIEW

There's a historical tendency for CVS to show strength heading into
flu season in multiple years. While no pattern is guaranteed,
seasonality matters most when it aligns with fundamentals and
sentiment.

In CVS’s case, the market has also been focused on operational
performance and outlook. Recent coverage has emphasized improved
guidance and expectations for continued momentum into 2026, which can
support the stock alongside any seasonal tailwind.

-------------------------

_American Alternative Asset_

WHY INSIDERS ARE WHISPERING “$24,000 GOLD”
[[link removed]]

It's not a conspiracy theory. It's historical math.

If gold were revalued to back just 17% of the U.S. national debt —
like it has in the past — it would need to be worth $24,000 an
ounce.

That number didn't come from speculation. It comes from the same
formula used during previous monetary resets.

And now Washington insiders, hedge fund billionaires, and even Trump
himself are openly discussing moves that point to a gold reset.

You won't hear this on CNBC.

But if you wait for headlines, you'll already be too late.

That's why we created the free report, Trump's $24,000 Panic Button.

It reveals the signals insiders are acting on — and shows how
everyday Americans can protect their retirement before this reset
hits.

[first ballot button]
[[link removed]]

-------------------------

_Are there any other seasonal Winter stocks you're buying right now?
What other sectors of the market are you currently interested in? Hit
"reply" to this email and let us know your thoughts!_

Our mailing address is:
Behind the Markets, LLC
4260 NW 1st Avenue, Suite 55
Boca Raton, FL 33431

Copyright © 2024 Behind the Markets, LLC, All rights reserved.
You're receiving this email as part of your subscription to Behind the
Markets. For more information about our privacy practices, please
review our Privacy Policy
[[link removed]]
or our Legal Notices.
[[link removed]]

Behind the Markets
[[link removed]]

Unsubscribe
[[link removed]]

invisiblelink
[[link removed]]